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Atopic dermatitis (AD) is generally regarded as a type 2 helper T (Th2)-mediated inflammatory skin disease.
Although the number of IL-17A-producing cells is increased in the peripheral blood and in acute skin lesion of AD
patients, the role of IL-17A in the pathogenesis of AD remains unclear. To clarify this issue, we used murine AD
models in an IL-17A-deficient condition. In a repeated hapten application–induced AD model, skin inflammation,
IL-4 production in the draining lymph nodes (LNs), and hapten-specific IgG1 and IgE induction were suppressed in
IL-17A-deficient mice. Vg4þ gd T cells in the skin-draining LNs and Vg5 dermal gd T cells in the skin were the
major sources of IL-17A. Consistently, in flaky-tail (Flgft/ft ma/ma) mice, spontaneous development of AD-like
dermatitis and IgE induction were attenuated by IL-17A deficiency. Moreover, Th2 differentiation from naive T cells
was promoted in vitro by the addition of IL-17A. Taken together, our results suggest that IL-17A mediates Th2-type
immune responses and that IL-17A signal may be a therapeutic target of AD.
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INTRODUCTION
Skin is an essential immune organ that can elicit a variety of
immune responses against foreign antigen exposure (Egawa
and Kabashima, 2011). Atopic dermatitis (AD) is a pruritic
chronic retractable inflammatory skin disease that is induced
by a complex interaction between susceptibility genes
encoding skin barrier components and stimulation by
environmental antigens (Palmer et al., 2006; Kabashima,
2012, 2013). AD is classically characterized by a type 2
helper T (Th2)–dominant condition, which seems to be
mediated by epidermal Langerhans cells stimulated with
thymic stromal lymphopoietin (TSLP) on keratinocytes
(Soumelis et al., 2002). TSLP also induces Th2 chemokines,
including thymus- and activation-regulated chemokine/
CCL17, and is involved in allergic responses, IgE production,
and eosinophilia (Liu et al., 2007; Nakajima et al., 2012).
IL-17A is known to be involved in host defense against
various pathogens. The inappropriate production of IL-17A is
considered to be involved in the development of Th17-
mediated autoimmune and inflammatory conditions, such as
multiple sclerosis, rheumatoid arthritis, and psoriasis (Iwakura
et al., 2011). Consistently, the IL-17A-Th17 pathway is a good
therapeutic target of psoriasis (Miossec and Kolls, 2012). IL-
17A is also involved in the pathogenesis of contact
hypersensitivity (CHS) responses, as the CHS response was
attenuated in IL-17A-deficient (IL-17A / ) mice via the
impaired expansion of hapten-specific CD4þ T cells in the
sensitization phase (Nakae et al., 2002; Honda et al., 2013).
Th17 axis in AD is known to be attenuated compared with
psoriasis, reflecting the model for AD as Th2/Th22 and
psoriasis as a Th1/Th17-polarized disease, respectively. This
is reflected in part by low levels of downstream molecules in
the Th17 pathway, including key antimicrobial peptides,
which is related to the increased infection rate seen in AD
(Ong et al., 2002).
In contrast, others and we have reported that the number of
IL-17A-producing cells is increased in the peripheral blood
mononuclear cells of patients with severe AD and at the acute
eczematous lesions of AD in humans (Toda et al., 2003; Koga
et al., 2008). Consistently, IL-17A was highly detected in the
spontaneously developed AD-like skin lesions in flaky-tail
(Flgft) mice, which carry mutations in filaggrin and matted
genes (Fallon et al., 2009; Oyoshi et al., 2009; Moniaga and
Kabashima, 2011).
In addition to CD4þ Th17 cells, subsets of CD8þ T cells,
gd T cells, natural killer T cells, monocytes, natural killer cells,
and lymphoid tissue inducer–like cells have been shown to
produce IL-17A (Cua and Tato, 2010). Among them, gd T cells
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produce IL-17A in psoriasis skin lesions in murine models and
human samples (Cai et al., 2011; Laggner et al., 2011). In
murine skin, there exist at least two populations of gd T cells:
Vg5þ gd TCRhighþ gd T cells in the epidermis and Vg5- gd
TCRmidþ gd T cells in the dermis. It has recently been revealed
that CCR6þ IL-23 receptor (IL23R)þ gd T cells are present in
the murine dermis (Gray et al., 2011), which secrete IL-17A
and IL-22 by responding to IL-23 and IL-1b (Sutton et al.,
2009; Cua and Tato, 2010), and that IgE induction is impaired
in gd T cell–deficient mice (Strid et al., 2011). Therefore, it is
important to determine which cells produce IL-17A and to
evaluate the role of IL-17A in the pathogenesis of AD.
RESULTS
IL-17A deficiency attenuated the development of hapten-
induced AD-like skin lesions
Single hapten elicitation (hereafter, called acute CHS) is
known to induce delayed-type hypersensitivity, as a murine
model of human contact dermatitis (Honda et al., 2013). On
the other hand, repeated hapten exposure (hereafter, called
chronic CHS) shifts immune responses from a typical Th1-
dominated delayed-type hypersensitivity response to a chronic
Th2-dominated late-phase and immediate-type hypersen-
sitivity response, which are clinically relevant to the acute
phase of AD in humans (Kitagaki et al., 1997; Man et al.,
2008; Jin et al., 2009; Hatano et al., 2010). Consistently,
recent studies have proposed that cutaneous exposure to
hapten contributes to the induction of AD—this is called the
hapten-atopy hypothesis (McFadden et al., 2011). We applied
this murine AD-like model to wild-type (WT) and IL-17A /
mice on BALB/c background.
In acute CHS, ear swelling 24 and 48 hours after application
(i.e., a delayed-type hypersensitivity reaction) was attenuated
in IL-17A / mice, as reported previously (Nakae et al.,
2002); (Figure 1a, upper panel), whereas ear swelling without
sensitization was comparable between WT and IL-17A /
mice. In chronic CHS, WT mice exhibited prominent
ear-swelling responses 1 and 6 hours after the last
hapten application, which were significantly attenuated in
IL-17A / mice (Figure 1a, lower panel). Histological exam-
ination of skin from WT mice revealed epidermal hyperplasia
with inflammatory cell infiltration, which is similar to acute
AD skin lesions (Figure 1b, Supplementary Table S1 online).
These findings were less apparent in IL-17A / mice
(Figure 1b; Supplementary Table S1 online). The total histo-
logical score of IL-17A / mice was significantly lower than
that of WT mice (Figure 1c).
To evaluate the extent of induction of Th2 in IL-17A /
mice, we analyzed cytokine mRNA expression levels of the
skin and draining lymph nodes (LNs) by quantitative PCR
analysis 6 hours after the last elicitation of chronic CHS and in
the steady state (indicated as control). Consistent with the
observation that IL-17A-producing cells are increased in
human AD (Toda et al., 2003; Koga et al., 2008), the IL-17A
expression levels of the skin and draining LNs were elevated
after repeated hapten exposures (Figure 2a). The IL-4 mRNA
expression levels of the skin and draining LNs in IL-17A /
mice were significantly decreased when compared with those
of WT mice (Figure 2a). On the other hand, the IFN-g, IL-10,
and IL-22 mRNA expression levels of the skin and draining
LNs did not show any significant differences between WT and
IL-17A / mice (Figure 2a).
It is known that IgE and IgG1 are Th2-dependent Igs and
that IgG2a is a Th1-dependent Ig, respectively (Snapper et al.,
1988a, b). Serum 4-ethoxymethlene-2-phenyloxazolin-5-one-
specific IgE, IgG1, and IgG2a levels in IL-17A / mice after
chronic CHS were significantly lower than those in WT mice
(Figure 2b). These data suggest that IL-17A is involved in the
development of both acute CHS (Th1) and chronic CHS (Th2)
models.
Th2 chemokine expression levels and IL-4-producing cells were
attenuated by IL-17A deficiency
TSLP and CCL17/thymus- and activation-regulated chemokine
have a pivotal role in Th2-mediated allergic response. We
therefore analyzed mRNA expression levels of these genes
6 hours after the last elicitation of chronic CHS. TSLP and
CCL17/thymus- and activation-regulated chemokine mRNA
levels in the ear skin were increased in WT mice. After
chronic CHS, the mRNA levels of TSLP and CCL17/thymus-
and activation-regulated chemokine in IL-17A / mice were
significantly lower than those in WT mice by 70 and 30%,
respectively (Figure 3a and b). The above findings suggest that
Th2 induction was impaired in IL-17A / mice. As such, we
focused on the IL-4 induction via IL-17A signaling.
Consistent with the mRNA analysis (Figure 2a), the number
of IL-4þ cells was increased in chronic CHS by intracellular
cytokine staining, and the number of IL-4þ cells in IL-17A /
mice was significantly lower than that in WT mice
(Figure 3c). In addition, the number of CD4þ IL-4þ Th2 cells
in IL-17A / mice was significantly lower than that in WT
mice (Figure 3d). It is known that naive T cells express IL-17R
(Ishigame et al., 2009); therefore, there is a possibility that
IL-17A may be involved in IL-4-producing Th2-cell
differentiation. To dissect the direct action of IL-17A in Th2
differentiation, we incubated naive CD4þ T cells under a
Th2-skewing condition in the presence or absence of IL-17A.
Under the Th2-skewing condition, the number of
IL-4-producing cells in CD4þ T cells was increased by
IL-17A under different anti-CD3/CD28 stimulation conditions
(Figure 3e). The above findings suggest that IL-17A may
contribute to Th2 differentiation in the draining LN.
cd T cells are the main producer of IL-17A
We examined the enhanced IL-17A mRNA expression after
repeated hapten application as above (Figure 2a). Next, we
confirmed this phenomenon using an intracellular cytokine
staining assay. The numbers of IL-17A-producing cells in the
skin-draining LNs (Figure 4a) and in the lesional skin
(Figure 4b) were increased after repeated hapten application.
The main producer of IL-17A in the skin-draining LNs was
Vg4þ gd TCRþ T cells (Figure 4a). In the skin, there exist at
least two gd T-cell subsets: Vg5þ epidermal gd T cells, and
Vg5 dermal gd T cells (Mabuchi et al., 2011). After repeated
hapten application, the number of CD45þ IL-17Aþ cells was
increased in the lesional skin, and the main producer of
S Nakajima et al.
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IL-17A was Vg5 dermal gd T cells (Figure 4b). Next,
we analyzed single-cell suspensions from the epidermis.
We detected major histocompatibility complex class II IL-17A-
producing cells in the epidermis, after repeated application,
and the majority of them were Vg5 gd T cells (Figure 5a and
b). This result suggests that IL-17A-producing dermal gd T cells
migrated into the epidermis after repeated hapten application.
IL-17A deficiency led to impaired Th2 induction in Flgft mice
Finally, we sought to evaluate the role of IL-17A in another
murine AD-like model, Flgft mice, which mutated in filaggrin
and matted genes. Tmem79 (ma/ma) mutation is responsible
for the spontaneous dermatitis phenotype in Flgft mice (Sasaki
et al., 2013; Saunders et al., 2013), and deficiency of filaggrin
gene alone does not induce spontaneous dermatitis (Kawasaki
et al., 2012). The Flgft mice exhibited Th17-dominant milieu
in the skin and skin-draining LNs (Fallon et al., 2009; Oyoshi
et al., 2009; Moniaga and Kabashima, 2011). We crossed Flgft
mice with IL-17A / mice on B6 background to evaluate the
role of IL-17A in the development of spontaneous AD-like skin
lesions in Flgft mice. Clinical appearance was mild in IL-
17A / Flgft mice when compared with Flgft mice at the age
of 20 weeks (Figure 6a, Supplementary Table S3 online).
Consistently, the histological score of IL-17A / Flgft mice
was lower than that of IL-17Aþ /þ Flgft mice (Figure 6b;
Supplementary Figure S2 online; Supplementary Table S2
online). We measured serum Th2-type Ig (IgE and IgG1) and
Th1-type Ig (IgG2c) levels, and found that IL-17A deficiency
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Figure 1. IL-17A deficiency attenuated the development of hapten-induced atopic dermatitis (AD)-like skin lesions. (a) Time course of antigen-specific
ear-swelling responses of wild-type (WT) mice and IL-17A / mice after the last elicitation with 4-ethoxymethlene-2-phenyloxazolin-5-one (OX) in acute
(upper) and chronic contact hypersensitivity (CHS; lower). In acute CHS, ear swelling of mice with (þ ) or without ( ) sensitization (sens) was shown.
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led to impaired IgE production in Flgft mice (Figure 6c),
whereas the levels of IgG1 and IgG2c were comparable
between these two groups (Figure 6c).
To further characterize the effect of IL-17A deficiency in
Flgft mice, we analyzed the compositions of LN and spleen
cells by means of flow cytometry. Although IL-17A deficiency
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did not attenuate spleen cells in B6 and Flgft mice, the
total cell numbers of LN cells and cell counts and frequencies
of CD4þ and CD8þ T-cell subsets were significantly
decreased in IL-17A / Flgft mice (Supplementary Figure
S3a and b online).
We then prepared single-cell suspensions from LNs and
stimulated them with phorbol 12-myristate 13-acetate/iono-
mycin for 4 hours to analyze the number of IL-4-producing
CD4þ T cells. The number of IL-4-producing CD4þ T cells in
IL-17A / Flgft mice was significantly decreased compared
with IL-17Aþ /þ Flgft mice (Figure 6d). These results suggest
that IL-17A facilitates Th2 induction in Flgft mice. In our study,
we observed that the IgE induction was attenuated in murine
AD-like models. It has been reported that IL-17A promotes IgE
production in B cells in humans in vitro (Doreau et al., 2009;
Milovanovic et al., 2010). Consistently, IL-17A marginally
promoted IgE production in B cells in a concentration-
dependent manner under indicated anti-CD40 antibody and
recombinant murine IL-4 concentrations (Figure 6e).
DISCUSSION
The roles of IL-17A in the induction of Th2 and the develop-
ment of AD remain to be elucidated. In this study, we sought
to clarify this issue using two AD-like murine models: a
repeated hapten application–induced chronic CHS model
and Flgft mice (Kitagaki et al., 1997; Spergel et al., 1998;
Moniaga et al., 2010). In the chronic CHS model, IL-17A-
producing cells were increased in the lesional skin and
draining LNs. The skin inflammation and IL-4 production
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were suppressed by IL-17A deficiency. Consistently, in Flgft
mice, AD-like dermatitis was attenuated by depletion of IL-
17A. In vitro Th2 differentiation from naive T cells was
enhanced by the addition of IL-17A. IL-17A deficiency
decreased TSLP and CCL17 expressions in chronic CHS,
which may contribute to the induction of Th2 indirectly.
These findings suggest that IL-17A mediates the development
of AD. The findings may be consistent with a recent report that
IL-17A-producing Th2 cells represent the key pathogenic Th2
cells that promote the exacerbation of allergic asthma in
humans (Wang et al., 2010).
On the other hand, IL-4 has been considered to inhibit IL-
17A production potentially (Eyerich et al., 2009). Consistently,
IL-17A-positive cells infiltrated into the lesions of AD more
attenuated in chronic lesions than in acute lesions (Koga et al.,
2008). In addition, Th17 axis in AD is rather attenuated
compared with psoriasis in humans. Therefore, although IL-
17A seems to promote Th2, IL-4 as a Th2 cytokine may
suppress IL-17A production as a feedback mechanism.
Intriguingly, the immune responses of IL-17A / mice
are impaired in Th1-based acute CHS and Th2-based
AD models (as shown in this study). Therefore, we speculate
that IL-17A works as the enhancer of both Th1 and Th2
differentiation depending on the cytokine milieu, although it
does not decide the direction of differentiation by itself.
We therefore suppose that IL-17A may not promote Th2-
dominated milieu under pure Th17 conditions in established
Th17 diseases.
The effect of IL-17A on IgE induction is another issue to be
addressed. We demonstrated that IL-17A deficiency decreased
Th2-type IgE production in Flgft mice, whereas IL-17A defi-
ciency decreased both Th1- and Th2-type Ig production in the
chronic CHS model. This difference may stem from the
differences of these models. Flgft mice exhibited Th2/Th17
conditions without induction of Th1, whereas the chronic
CHS model exhibited Th2 conditions by shifting from Th1
conditions upon repeated hapten application. The mechan-
isms of IgE production and class switching from IgG1 to IgE
remain unclear. The patients of classical-type hyper-IgE
syndrome due to dominant-negative mutations in the STAT3
(signal transducer and activator of transcription-3) gene exhibit
high concentrations of IgE, as contrasted with normal serum
levels of all other Igs (IgG, IgA, IgM, and IgD) and IgG
subclasses (Minegishi, 2009). Moreover, a recent study
demonstrated that STAT3 expression on Th2 cells regulates
class switch from IgG1 to IgE in vitro and in vivo (Mari et al.,
2013). Therefore, the dependency of STAT3 for the induction
of IgE may vary between the chronic hapten application–
induced AD model and Flgft mice, which may explain the
different phenotypes between these two groups.
Given that this study was conducted in mice, there are
limitations when translating the findings to humans. These
points may include the following: (1) we used the mouse
model rather than human AD skin or blood samples; (2) we
applied the hapten-induced murine AD-like model, which
may induce nonspecific immune activation of several inflam-
matory axes as reported (He et al., 2008; Jin et al., 2009), and
it might be difficult to draw conclusions in humans from this
model; (3) in humans, the functional role for gd T cells remains
unclear in terms of IL-17 production; it has not been
demonstrated in humans unlike mice. We agree that there
still remain limitations in this study, but our findings suggest
that IL-17A mediates Th2-type immune responses in the
perspective of the development of AD, and that IL-17A
signal may be a therapeutic target of AD.
MATERIALS AND METHODS
Mice
C57BL/6NCrSlc (B6) and BALB/c mice were purchased from Japan
SLC (Shizuoka, Japan). IL-17A / mice on B6 and BALB/c genetic
backgrounds were generated (Nakae et al., 2002). Flaky-tail mice
(STOCK a/a ma ft/ma ft/J; Flgft mice; Fallon et al., 2009; Moniaga
et al., 2010) were backcrossed more than six generations onto B6
mice background. IL-17A enhanced green fluorescent protein reporter
mice were kindly provided by Dr Masato Kubo. Seven- to 12-week-
old female mice that were bred in specific pathogen-free facilities at
Kyoto University were used for all experiments, which were approved
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by the Institutional Animal Care and Use Committee of Kyoto
University Graduate School of Medicine.
Acute and chronic CHS
The acute CHS reaction to hapten is an animal model of human
allergic contact dermatitis (Honda et al., 2013). For sensitization,
the shaved abdominal skin was applied with 25ml of 3%
4-ethoxymethlene-2-phenyloxazolin-5-one (Wako, Osaka, Japan)
solution in ethanol (day 0). For acute CHS induction, 5 days after the
initial abdominal application when sensitization was established, 20ml
of 0.6% 4-ethoxymethlene-2-phenyloxazolin-5-one solution was
applied to the ear (Supplementary Figure S1a online). For chronic
CHS induction, 4-ethoxymethlene-2-phenyloxazolin-5-one solution
was applied to the ear every other day until day 13 (Supplementary
Figure S1b online). Ear thicknesses were measured using a micrometer
before (0 h) and 1, 6, 24, and 48 h after elicitation. The differences
between the indicated time points and 0 h were referred to as ear
swelling. Immediate-type, late-phase, and delayed-type hypersensitivity
reactions were manifested by ear-swelling responses at 1, 6, and 24 h
after the last hapten application, respectively. Histology was obtained
6 h after the last hapten application (Supplementary Figure S1b online).
Quantitative reverse transcription–PCR analysis
We collected ears and cervical LNs 6 hours after the last elicitation to
analyze cytokine mRNA expression levels. Total RNA was isolated
with RNeasy kits and DNase I (Qiagen, Hilden, Germany). Com-
plementary DNA was reverse transcribed using the Prime Script RT
reagent kit (Takara Bio, Otsu, Japan). Quantitative PCR analysis was
performed as reported previously (Nakajima et al., 2010). All primers
were obtained from Greiner Japan (Tokyo, Japan). The primer
sequences were as follows: IFN-g, 50-GAA CTG GCA AAA GGA
TGG TGA-30 (forward), 50-TGT GGG TTG TTG ACC TCA AAC-30
(reverse); IL-4, 50-GGT CTC AAC CCC CAG CTA GT-30 (forward), 50-
GCC GAT GAT CTC TCT CAA GTG AT-30 (reverse); IL-17A, 50-CTC
CAG AAG GCC CTC AGA CTA C-30 (forward), 50-GGG TCT TCA
TTG CGG TGG-30 (reverse); IL-10, 50-GCT CTT ACT GAC TGG CAT
GAG-30 (forward), 50-CGC AGC TCT AGG AGC ATG TG-30 (reverse);
CCL17, 50-CAG GGA TGC CAT CGT GTT TCT-30 (forward), and
50-GGT CAC AGG CCG TTT TAT GTT-30 (reverse). For each sample,
triplicate test reactions and a control reaction lacking reverse
transcriptase were analyzed for expression of the genes, and the
results were normalized to those of ‘‘housekeeping’’ glyceraldehyde-
3-phosphate dehydrogenase mRNA.
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Figure 6. IL-17A deficiency attenuated cutaneous inflammation and type 2 helper T (Th2) induction in Flgft mice. (a, b) Clinical findings and total clinical
scores (a) and histology scores (b) of IL-17þ /þ and IL-17 / Flgft mice. Arrows indicate erosion of the skin. (c) Serum IgE, IgG1, and IgG2c levels. (d) The number
of IL-4-producing CD4þ T cells. (e) Class switch recombination assay. The number of IgE-producing splenic CD19þ B220þ cells in various concentrations
of IL-17A. *Po0.05 (n¼5 per group).
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Th2 differentiation assay
Naive CD4þ T cells were sorted with the autoMACS separator
(Miltenyi Biotec, Bergisch Gladbach, Germany); the purity was
495%. For an in vitro Th2 differentiation assay, BALB/c naive
CD4þ CD62Lþ T cells were stimulated for 2 days with plate-bound
anti-CD3 (1mg ml 1) and plate-bound anti-CD28 (1 or 10mg ml 1) in
the presence of 10 ng ml 1 IL-4, 10mg ml 1 anti-IFN-g Ab, and
20 ng ml 1 IL-2. Forty-eight hours after the primary stimulation, cells
were washed and cultured for 72 hours under the Th2-skewing
conditions without anti-CD3 or anti-CD28 Ab stimulation.
Class switch recombination assay in vitro
Splenocyte single-cell suspensions were isolated by CD19þ selection
via magnetic columns (Miltenyi Biotec). CD19þ cells (5 105) were
cultured in flat-bottomed 24-well plates and stimulated with
1mg ml 1 of anti-CD40 antibody (BD Bioscience, San Diego, CA)
plus 50 ng ml 1 of recombinant mouse IL-4 (R&D Systems, Minnea-
polis, MN) for 6 days to induce class switching to IgE. IgE-producing
cells were analyzed by flow cytometry.
Statistical analysis
Unless otherwise indicated, data are presented as the means±SD and
are representative of three independent experiments. P-values were
calculated according to the two-tailed t-test and the Mann–Whitney
U-test for independent samples and the Wilcoxon test for related
samples. P-valueso0.05 are considered to be significant and are
marked by an asterisk in the figures.
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